Climaco John M 4
4 · CNS Pharmaceuticals, Inc. · Filed Mar 31, 2023
Insider Transaction Report
Form 4
Climaco John M
DirectorChief Executive Officer
Transactions
- Award
Restricted Stock Units
2023-03-29+16,467→ 61,451 total→ Common stock (16,467 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock.
- [F2]The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events).
- [F3]Issued in connection with the reporting person's employment with the Company.